Emergency Department of University Hospital Grenoble
Grenoble, Auvergne Rhonalpes, 38043, France
NCT Number: NCT03474575
The prevalence of chronic obstructive pulmonary disease (COPD) is between 8 and 15% of the adult population in 2010. This prevalence is expected to increase over the coming decades as the population ages and exposure to the risk factors for the disease continues. The evolution of COPD is marked by the occurrence of exacerbations of varying severity responsible for 1% of emergency department admission. Thus,95% of COPD patients admitted to emergency department for exacerbation are hospitalized.
Several recent studies seem to show that an early discharge from hospital with home care can reduce the rate of rehospitalisation and mortality of COPD patients. These preliminary data on low numbers need to be confirmed. In addition, it seems necessary to identify the phenotypes of patients who benefit most from these early exits.
Exadom project (supported by Rhône-Alpes-Auvergne Regional Health Authorities (ARS), AstraZeneca and Grenoble Alpes University Hospital) aims to establish a safe and effective way of discharging patients by providing enhanced home-based care for AECOPD.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Not applicable
Grenoble, Auvergne Rhonalpes, 38043, France
Exadom project (supported by Rhône-Alpes-Auvergne Regional Health Authorities (ARS) , Grenoble Alpes University Hospital) aims to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
This program implements ambulatory care immediately after leaving the emergency department with a main goal of reducing hospital readmission during the first month. The home-based support includes daily visits at home conducted by the home care provider's nurses from day 1 to day 7, telephone calls at days 14 and 21 and a final home visit one month after discharge from the emergency department. Blood samples will be collected at inclusion, day 7 and one month during home visit and urine samples at inclusion, day 2, day 4 and one month during home visit .Telephone follow-up at 3, 6 months and one year.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
Time frame: 90 days
number of an hospitalization being an entry in any hospital or clinic , whatever the length of the stay
Time frame: 6 months and one year
number of an hospitalization being an entry in any hospital or clinic , whatever the length of the stay for all cause
Time frame: 3,6 and 12 months
number of an hospitalization being an entry in any hospital or clinic , whatever the length of the stay for COPD exacerbation aggravation
Time frame: one year
number of hospitalizations due to myocardial infarction, cardiac failure, stroke
Time frame: 3, 6 and 12 months
number of death
Time frame: 30 days
measures of biological and clinical markers collected at baseline and at day 30
Time frame: 30 days
Differential measurements of biological and clinical markers between day 30 and at inclusion
Time frame: 3 months
comparaison between early discharge patient with ambulatory care group and patient with standard care (historical cohort)
Time frame: 1 year
Measured on the basis of a refusal register
University Hospital, Grenoble
Other
EXADOM: Early Supported Discharge and Enhanced Homecare After Emergency Department Admission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Acronym: EXADOM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT06614959
Bronchial Diseases, Bronchitis
Montreal, Quebec, Canada
View Trial DetailsNCT04754490
COPD, Chronic Disease
Abercynon, Wales, United Kingdom
View Trial DetailsNCT06336252
Arthritis, Basal Ganglia Diseases
Copenhagen, Denmark
View Trial Details